3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Breast
1
Conditions
Stomach Neoplasms
1
Rectal Neoplasms
1
Peutz-Jeghers Syndrome
1
Pancreatic Neoplasms
1
Pancreatic Cyst
1
Neoplastic Cells, Circulating
1
Hereditary pancreatitis
1
Hereditary Sensory and Autonomic Neuropathies
1
Dysplastic Nevus Syndrome
1
Colorectal Neoplasms, Hereditary Nonpolyposis
1
Breast Neoplasms
1
Interventions
Everolimus
5
Cetuximab
2
volagidemab
1
tanezumab
1
pembrolizumab
1
inavolisib
1
Vemurafenib
1
Trimetazidine
1
Sirolimus
1
Secretin
1
SF 1126
1
Pharmaceutical Preparations
1
Panobinostat
1
Oxaliplatin
1
Nivolumab
1
NVP-BKM120
1
Leucovorin
1
Irinotecan
1
Fulvestrant
1
Fluorouracil
1
Drug Therapy
1
Capecitabine
1
CB-839
1
CA-19-9 Antigen
1
Bevacizumab
1
Aspirin
1
Alpelisib
1
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Hereditary Sensory and Autonomic Neuropathies
×
CA-19-9 Antigen
×
Clear all
NCT02000089
2025-10-09
CAPS5
Johns Hopkins University
Phase 3
Recruiting
9,000 enrolled